Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Emerald Wealth Partners - Growth Equity Strategy Portfolio Manager | “Advantest is one of the most prominent beneficiaries of the surge in demand not only for AI-chips, but high-end semis in general. Advanced chips for AI will use 2-nanometer and 3nm technology that requires high-quality testers. New DRAM chips known as high-bandwidth-memory (HBM) chips are set to be widely adopted due to generative AI, fueling revenue growth for memory testers and the mechatronics division in the years to come. As importantly, there are only two major testing companies left (Advantest and Teradyne), but Advantest dominates AI-testing while innovating at a rapid pace. Based on our two on-site visits and developments since, we believe that Advantest is also the innovation leader among the two. Even though the stock has gone up 6-fold since our initial purchase two years ago and valuation is demanding, the fundamental outlook remains highly promising. What's more, since testing is only a small percentage of semi-spend (1%) and the need for more intense and advanced testing is likely to continue to grow, estimates are likely to continue rising as a consequence. Hence, despite the high valuation, we stay the course.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
